Dr. Joyce transfers Village Oaks Pathology equity to Dr. Humphreys; new succession agreement executed

bioAffinity Technologies, Inc.

Dr. Joyce (77) informed Company of desire to transfer 100% stock of Village Oaks Pathology to Dr. Humphreys; not due to disagreement.
On Dec 22, 2025, Village Oaks Pathology, PPLS, and Dr. Humphreys entered a Succession Agreement restricting disposal of equity.
Agreement provides for automatic transfer of equity to a successor upon death, disability, retirement, incompetence, or failure to meet eligibility requirements.
Dr. Humphreys must use commercially reasonable efforts to preserve Village Oaks Pathology's operations, contracts, and licenses.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.